(Source: Global Blood Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., July 8, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced publication of preclinical GBT440 results in sickle cell disease (SCD) in the July 5 online edition of the British Journal of Haematology, http://onlinelibrary.wiley.com/doi/10.1111/bjh.14214/abstract. GBT440 is a novel small molecule that binds specifically to hemoglobin (the oxygen-carrying protein in red blood cells) and is designed to inhibit sickle hemoglobin (HbS) polymer formation....
↧